Every 424B that Autonomix Medical, Inc. (AMIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AMIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMIX filings page.
Autonomix Medical, Inc. (AMIX) has established an at-the-market equity program under which it may sell shares of common stock with an aggregate offering price of up to $10.525 million from time to time through Ladenburg Thalmann as sales agent or principal. Ladenburg will receive a 3.0% cash commission on gross proceeds and may also conduct privately negotiated transactions, with no minimum sale amount and no escrow arrangement. Based on a September 8, 2026 closing price of $4.58 and 1,959,938 shares outstanding, the company illustrates that issuing 2,298,035 shares would increase shares outstanding to 4,257,973, subject to the 500,000,000 authorized share limit and one‑third public float constraints under Form S‑3 Instruction I.B.6. Autonomix intends to use any net proceeds for working capital and general corporate purposes. The company is a development‑stage medical device business with no product sales revenue, an auditor’s going‑concern explanatory paragraph, and significant risks including potential Nasdaq delisting if a new $5 million Market Value of Listed Securities rule ultimately takes effect and is not satisfied, as well as dilution and price volatility from this ATM program.
Autonomix Medical, Inc. is conducting a primary at‑the‑market equity program, registering up to $1.35 million of common stock to be sold from time to time through Ladenburg Thalmann as sales agent or principal under an ATM Agreement.
The company had 971,043 shares outstanding as of July 29, 2026, with a potential increase to up to 1,266,447 shares based on an illustrative 295,404 shares sold at an assumed price of $4.57. Autonomix intends to use any net proceeds for working capital and general corporate purposes.
The filing highlights significant risks, including potential dilution, limited trading liquidity, dependence on additional financing, and exposure to Nasdaq’s new $5.0 million Market Value of Listed Securities requirement, which, if implemented and not met, could result in an immediate suspension and delisting of the stock. Audited financials also include a going‑concern explanatory paragraph.
Autonomix Medical, Inc. has filed a prospectus covering the resale of up to 13,504,998 shares of common stock issuable upon exercise of outstanding warrants issued in a November 2025 PIPE transaction. This includes 9,003,332 shares underlying Series C common stock purchase warrants and 4,501,666 shares underlying pre-funded warrants. The company will not receive any proceeds from share resales by the selling stockholder but could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash, which it plans to use for working capital and general corporate purposes.
The warrants are immediately exercisable, with Common Warrants priced at $0.8607 per share and expiring five and a half years after issuance, and Pre-Funded Warrants priced at $0.001 per share and expiring when fully exercised. Shares outstanding were 6,907,678 as of November 21, 2025. The filing highlights that registering a large number of resale shares could pressure the stock price and materially dilute existing holders, and notes an auditor going concern paragraph regarding the company’s ability to continue as a going concern.